Lenalidomida Sandoz

Lenalidomide, the active ingredient in Lenalidomida Sandoz, is an immunomodulatory agent presented as an oral formulation for oral use. It treats multiple myeloma, myelodysplastic syndromes with del(5q), and mantle cell lymphoma in adult patients. It is indicated for adult patients with specific hematologic cancers and is administered under medical supervision.

GNH USA supplies Lenalidomida Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide. The company follows Good Distribution Practice, ensures product integrity, and provides regulatory documentation to support import and clinical use.

Lenalidomida Sandoz is employed in hematologic malignancies that involve abnormal plasma or lymphoid cells.

- Multiple myeloma: reduces disease progression, improves overall survival, delays the need for subsequent therapy in adult patients, and enhances quality of life. - Myelodysplastic syndromes with del(5q): induces transfusion independence, promotes cytogenetic remission, improves hematologic parameters, while reducing dependence on supportive care. - Mantle cell lymphoma: provides therapeutic benefit in relapsed or refractory disease, contributing to tumor shrinkage, disease control, and may extend progression‑free survival.

Lenalidomida Sandoz may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Neutropenia: decreased neutrophil count, increasing infection risk. - Thrombocytopenia: reduced platelet levels, may cause bruising. - Anemia: lowered red blood cell count leading to fatigue. - Fatigue: general feeling of tiredness. - Diarrhea: loose stools. - Rash: mild skin irritation.

Serious or Rare Side Effects: - Venous thromboembolism: deep vein thrombosis or pulmonary embolism. - Secondary primary malignancies: emergence of new cancers. - Severe cutaneous reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Hepatotoxicity: elevated liver enzymes or liver injury.

Before prescribing Lenalidomida Sandoz, clinicians should consider several precautionary measures to minimize risks.

- Pregnancy contraindication: drug is category X and must not be used during pregnancy. - Contraception requirement: both male and female patients of reproductive potential must use effective contraception. - Thromboembolic risk: assess for risk factors and consider prophylactic anticoagulation. - Renal impairment: dose adjustment may be needed in patients with reduced kidney function. - Hepatic impairment: monitor liver function tests and adjust therapy if necessary. - Store at ambient temperature: keep below 25 °C in original packaging, protect from moisture.

Lenalidomida Sandoz can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce lenalidomide exposure. - Anticoagulants (warfarin, DOACs): increased risk of bleeding when combined. - Immunosuppressants (e.g., cyclosporine): may enhance immunosuppressive effects.

Moderate Interactions (Monitor Closely): - P-glycoprotein inhibitors (e.g., verapamil): may increase plasma levels. - CYP3A4 inhibitors (e.g., ketoconazole): may modestly raise exposure. - Vaccines: live vaccines should be avoided due to immunomodulation. - Herbal supplements (e.g., St. John’s wort): may alter drug metabolism and require monitoring.